Sulfisoxazole

Found 17 Sample Hits

m/z	Adducts	Species	Organ	Scanning	Sample
268.0722	[M+H]+ PPM:10.6	Homo sapiens	Liver	MALDI (DHB)	20171107_FIT4_DHBpos_p70_s50 - Rappez et al (2021) SpaceM reveals metabolic states of single cells Resolution: 50μm, 70x70 Description
250.0617	[M+H-H2O]+ PPM:11.1	Posidonia oceanica	root	MALDI (CHCA)	20190614_MS1_A19r-20 - MTBLS1746 Resolution: 17μm, 262x276 Description Seagrasses are one of the most efficient natural sinks of carbon dioxide (CO2) on Earth. Despite covering less than 0.1% of coastal regions, they have the capacity to bury up to 10% of marine organic matter and can bury the same amount of carbon 35 times faster than tropical rainforests. On land, the soil’s ability to sequestrate carbon is intimately linked to microbial metabolism. Despite the growing attention to the link between plant production, microbial communities, and the carbon cycle in terrestrial ecosystems, these processes remain enigmatic in the sea. Here, we show that seagrasses excrete organic sugars, namely in the form of sucrose, into their rhizospheres. Surprisingly, the microbial communities living underneath meadows do not fully use this sugar stock in their metabolism. Instead, sucrose piles up in the sediments to mM concentrations underneath multiple types of seagrass meadows. Sediment incubation experiments show that microbial communities living underneath a meadow use sucrose at low metabolic rates. Our metagenomic analyses revealed that the distinct community of microorganisms occurring underneath meadows is limited in their ability to degrade simple sugars, which allows these compounds to persist in the environment over relatively long periods of time. Our findings reveal how seagrasses form blue carbon stocks despite the relatively small area they occupy. Unfortunately, anthropogenic disturbances are threatening the long-term persistence of seagrass meadows. Given that these sediments contain a large stock of sugars that heterotopic bacteria can degrade, it is even more important to protect these ecosystems from degradation.
250.0623	[M+H-H2O]+ PPM:8.7	Posidonia oceanica	root	MALDI (CHCA)	20190613_MS1_A19r-18 - MTBLS1746 Resolution: 17μm, 246x264 Description
250.0617	[M+H-H2O]+ PPM:11.1	Posidonia oceanica	root	MALDI (CHCA)	MS1_20180404_PO_1200 - MTBLS1746 Resolution: 17μm, 193x208 Description
268.0752	[M+H]+ PPM:0.6	Homo sapiens	esophagus	DESI ()	LNTO22_1_4 - MTBLS385 Resolution: 17μm, 82x80 Description
268.075	[M+H]+ PPM:0.1	Homo sapiens	colorectal adenocarcinoma	DESI ()	80TopL, 50TopR, 70BottomL, 60BottomR-profile - MTBLS415 Resolution: 17μm, 137x136 Description The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024).
268.077	[M+H]+ PPM:7.3	Homo sapiens	esophagus	DESI ()	LNTO29_16_3 - MTBLS385 Resolution: 17μm, 108x107 Description
268.0771	[M+H]+ PPM:7.7	Homo sapiens	esophagus	DESI ()	TO31T - MTBLS385 Resolution: 75μm, 56x54 Description
268.0772	[M+H]+ PPM:8.1	Homo sapiens	esophagus	DESI ()	TO29T - MTBLS385 Resolution: 75μm, 56x48 Description
268.0772	[M+H]+ PPM:8.1	Homo sapiens	esophagus	DESI ()	LNTO22_1_7 - MTBLS385 Resolution: 75μm, 69x54 Description
268.0768	[M+H]+ PPM:6.6	Homo sapiens	esophagus	DESI ()	LNTO22_1_8 - MTBLS385 Resolution: 75μm, 69x61 Description
268.0769	[M+H]+ PPM:7	Homo sapiens	esophagus	DESI ()	LNTO30_7_2 - MTBLS385 Resolution: 75μm, 82x68 Description
268.0767	[M+H]+ PPM:6.2	Homo sapiens	colorectal adenocarcinoma	DESI ()	240TopL, 210TopR, 230BottomL, 220BottomR-centroid - MTBLS176 Resolution: 50μm, 142x141 Description
268.077	[M+H]+ PPM:7.3	Homo sapiens	colorectal adenocarcinoma	DESI ()	200TopL, 170TopR, 190BottomL, 180BottomR-centroid - MTBLS176 Resolution: 50μm, 132x126 Description
268.0767	[M+H]+ PPM:6.2	Homo sapiens	colorectal adenocarcinoma	DESI ()	160TopL,130TopR,150BottomL,140BottomR-centroid - MTBLS176 Resolution: 50μm, 142x136 Description
268.0769	[M+H]+ PPM:7	Homo sapiens	colorectal adenocarcinoma	DESI ()	120TopL, 90TopR, 110BottomL, 100BottomR-centroid - MTBLS176 Resolution: 50μm, 132x136 Description
268.0714	[M+H]+ PPM:13.6	Drosophila melanogaster	brain	MALDI (DHB)	Drosophila18 - 2019-10-16_14h26m34s Resolution: 5μm, 686x685 Description Sample information Organism: Drosophila melanogaster Organism part: Brain Condition: Healthy Sample preparation Sample stabilisation: Frozen Tissue modification: Frozen MALDI matrix: 2,5-dihydroxybenzoic acid (DHB) MALDI matrix application: TM sprayer Solvent: Aceton/water MS analysis Polarity: Positive Ionisation source: Prototype Analyzer: Orbitrap Pixel size: 5μm × 5μm Annotation settings m/z tolerance (ppm): 3 Analysis version: Original MSM Pixel count: 469910 Imzml file size: 696.23 MB Ibd file size: 814.11 MB

Sulfisoxazole is only found in individuals that have used or taken this drug. It is a short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3072; ORIGINAL_PRECURSOR_SCAN_NO 3068 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6520; ORIGINAL_PRECURSOR_SCAN_NO 6519 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3077; ORIGINAL_PRECURSOR_SCAN_NO 3073 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6493; ORIGINAL_PRECURSOR_SCAN_NO 6491 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6549; ORIGINAL_PRECURSOR_SCAN_NO 6547 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3096; ORIGINAL_PRECURSOR_SCAN_NO 3094 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3126; ORIGINAL_PRECURSOR_SCAN_NO 3125 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6542; ORIGINAL_PRECURSOR_SCAN_NO 6539 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6522; ORIGINAL_PRECURSOR_SCAN_NO 6521 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6555; ORIGINAL_PRECURSOR_SCAN_NO 6553 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3083; ORIGINAL_PRECURSOR_SCAN_NO 3080 CONFIDENCE standard compound; INTERNAL_ID 636; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3067; ORIGINAL_PRECURSOR_SCAN_NO 3065 J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01E - Sulfonamides and trimethoprim > J01EB - Short-acting sulfonamides S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AB - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides CONFIDENCE standard compound; INTERNAL_ID 1013 Sulfisoxazole (Sulfafurazole) is an orally active endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial agent with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A[1][2].